CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston, MA. The company's management will engage in a fireside chat on Tuesday, August 13, 2024, at 12:30 PM ET.
Investors can access the webcast of the fireside chat through a provided link or via the Investors section of CervoMed's website. Additionally, the company will be available for one-on-one investor meetings during the conference, offering an opportunity for more in-depth discussions about CervoMed's progress and future plans in the field of neurologic disorder treatments.
CervoMed Inc. (NASDAQ: CRVO), una società in fase clinica che sviluppa trattamenti per i disturbi neurologici legati all'età, ha annunciato la sua partecipazione alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity che si terrà a Boston, MA. La direzione dell’azienda parteciperà a un colloquio informale il martedì 13 agosto 2024, alle 12:30 PM ET.
Gli investitori possono accedere alla trasmissione in diretta del colloquio tramite un link fornito o attraverso la sezione Investitori del sito web di CervoMed. Inoltre, l’azienda sarà disponibile per incontri one-to-one con gli investitori durante la conferenza, offrendo l'opportunità di discussioni più approfondite sui progressi e i piani futuri di CervoMed nel campo dei trattamenti per i disturbi neurologici.
CervoMed Inc. (NASDAQ: CRVO), una empresa en etapa clínica que desarrolla tratamientos para trastornos neurológicos relacionados con la edad, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity en Boston, MA. La dirección de la empresa participará en una conversación informal el martes 13 de agosto de 2024, a las 12:30 PM ET.
Los inversores pueden acceder a la transmisión en vivo de la conversación a través de un enlace proporcionado o mediante la sección de Inversores en el sitio web de CervoMed. Además, la empresa estará disponible para reuniones individuales con los inversores durante la conferencia, brindando la oportunidad de discusiones más profundas sobre el progreso y los planes futuros de CervoMed en el campo de los tratamientos para trastornos neurológicos.
CervoMed Inc. (NASDAQ: CRVO), 노화 관련 신경 장애 치료제를 개발 중인 임상 단계 회사는 Canaccord Genuity 제44회 연례 성장 컨퍼런스에 참석한다고 발표했습니다. 회사의 경영진은 2024년 8월 13일 화요일 오후 12시 30분 ET에 파이어사이드 차트에 참여할 예정입니다.
투자자는 제공된 링크 또는 CervoMed 웹사이트의 투자자 섹션을 통해 파이어사이드 차트의 웹캐스트에 접근할 수 있습니다. 또한, 회사는 컨퍼런스 기간 동안 개별 투자자 회의를 위해 이용 가능하며, 신경 장애 치료 분야에서 CervoMed의 진행 상황 및 향후 계획에 대한 심층 논의의 기회를 제공합니다.
CervoMed Inc. (NASDAQ: CRVO), une entreprise en phase clinique développant des traitements pour les troubles neurologiques liés à l'âge, a annoncé sa participation à la 44ème Conférence Annuelle de Croissance de Canaccord Genuity à Boston, MA. La direction de l'entreprise participera à une discussion informelle le mardi 13 août 2024 à 12h30 ET.
Les investisseurs peuvent accéder à la retransmission en direct de la discussion via un lien fourni ou par la section Investisseurs du site web de CervoMed. De plus, l’entreprise sera disponible pour des réunions individuelles avec les investisseurs pendant la conférence, offrant l'opportunité de discussions approfondies sur les avancées et les futurs projets de CervoMed dans le domaine des traitements des troubles neurologiques.
CervoMed Inc. (NASDAQ: CRVO), ein Unternehmen in der klinischen Phase, das Behandlungen für altersbedingte neurologische Störungen entwickelt, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity in Boston, MA, angekündigt. Das Management des Unternehmens wird am Dienstag, den 13. August 2024, um 12:30 PM ET an einem Gespräch teilnehmen.
Investoren können auf den Webcast des Gesprächs über den bereitgestellten Link oder über den Investorenbereich der CervoMed-Website zugreifen. Darüber hinaus wird das Unternehmen während der Konferenz für Eins-zu-eins-Investorengespräche zur Verfügung stehen, um die Möglichkeit für ausführlichere Diskussionen über CervoMeds Fortschritte und zukünftige Pläne im Bereich der Behandlungen für neurologische Störungen zu bieten.
- None.
- None.
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s Management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, MA, and participate in one-on-one investor meetings.
Presentation Details
Format: Fireside Chat
Date: Tuesday, August 13, 2024
Time: 12:30 PM ET
Webcast Link: https://wsw.com/webcast/canaccord98/crvo/2485318
The webcast of the fireside chat will be accessible in the Investors section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
When is CervoMed (CRVO) participating in the Canaccord Genuity Growth Conference?
Where can investors watch CervoMed's (CRVO) fireside chat at the Canaccord conference?
What type of treatments is CervoMed (CRVO) developing?
Will CervoMed (CRVO) be available for one-on-one meetings at the Canaccord conference?
What is the format of CervoMed's (CRVO) presentation at the Canaccord conference?
